PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-13.58%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-21.95%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-32.27%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-195.63%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
167.94%
Positive net income growth while CSIQ is negative. John Neff might see a big relative performance advantage.
168.87%
Positive EPS growth while CSIQ is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
155.10%
Positive diluted EPS growth while CSIQ is negative. John Neff might view this as a strong relative advantage in controlling dilution.
1.77%
Share count expansion well above CSIQ's 0.92%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
18.91%
Slight or no buyback while CSIQ is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-86.96%
Negative OCF growth while CSIQ is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-82.83%
Negative FCF growth while CSIQ is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
204.54%
10Y revenue/share CAGR under 50% of CSIQ's 6693.63%. Michael Burry would suspect a lasting competitive disadvantage.
-29.48%
Negative 5Y CAGR while CSIQ stands at 48.75%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-43.62%
Negative 3Y CAGR while CSIQ stands at 41.45%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-246.13%
Negative 10Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-122.15%
Negative 5Y OCF/share CAGR while CSIQ is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-319.20%
Negative 3Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
113.47%
Below 50% of CSIQ's 818.14%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
174.47%
5Y net income/share CAGR at 50-75% of CSIQ's 326.26%. Martin Whitman might see a shortfall in operational efficiency or brand power.
106.82%
3Y net income/share CAGR 50-75% of CSIQ's 154.25%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-25.53%
Negative 5Y equity/share growth while CSIQ is at 26.50%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
16.39%
Below 50% of CSIQ's 40.41%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.43%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
2.59%
Inventory shrinking or stable vs. CSIQ's 30.22%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
5.98%
Asset growth at 50-75% of CSIQ's 11.41%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
1.39%
Under 50% of CSIQ's 4.66%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-4.55%
We’re deleveraging while CSIQ stands at 24.25%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-2.87%
Our R&D shrinks while CSIQ invests at 11.59%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
5.58%
We expand SG&A while CSIQ cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.